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ABSTRACT
Introduction: Metformin is among the most
frequently prescribed drugs worldwide for a
variety of indications. Although metformin has
several important advantages, for example
being easy to store and administer, it is associ-
ated with a high incidence of gastrointestinal
side effects. Slower-release formulations of
metformin may reduce the incidence of side
effects while maintaining efficacy; however,
there is a lack of systematic evidence available
to guide head-to-head comparisons between
different metformin formulations.
Methods: PubMed, Web of Science, OVID
EMBASE, MEDLINE, The Cochrane database
and Clinicaltrials.gov were systematically sear-
ched (from inception to 25 January 2021). Trials
that randomized adult participants to extended-
release formulation of metformin (met-XR),
delayed-release (met-DR) or immediate-release
metformin (met-IR) were included. Two
reviewers independently assessed articles for
eligibility and risk-of-bias, with conflicts
resolved by a third reviewer. Outcome measures
were change in fasting plasma glucose (FPG),
glycated haemoglobin (HbA1c), body weight,
BMI, lipid profile and side effects. Meta-analyses
were conducted using random-effects models.
Results: Fifteen studies (n = 3765) met eligibil-
ity criteria. There was no significant difference
between the efficacy of met-IR, met-XR or met-
DR in changing FPG (p = 0.93). A non-signifi-
cant reduction in mean body weight was
observed in individuals randomized to met-XR
vs. met-IR (- 1.03 kg, 95% CI - 2.12 to 0.05,
p = 0.06). Individuals randomized to met-XR vs.
met-IR had lower low-density lipoprotein (LDL)
cholesterol levels (- 5.73 mg/dl, 95% CI - 7.91
to - 3.56, p\0.00001). Gastrointestinal (GI)
side effects were markedly reduced in patients
randomised to met-DR vs. met-IR (OR 0.45, 95%
CI 0.26–0.80, p = 0.006).
Conclusion: Our results demonstrate equal
efficacy of longer-acting formulations (met-XR,
met-DR) versus immediate-release metformin
formulations in terms of glycaemic control.
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There were insufficient studies available to
compare the efficacy of different metformin
formulations outside of diabetes care. However
met-XR was associated with reduced serum LDL
cholesterol concentrations, while met-DR was
strongly associated with reduced GI side effects,
which could improve drug compliance.
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Key Summary Points
Why carry out this study?
Despite the very widespread clinical use of
metformin, there is a lack of systematic
evidence to guide optimal selection of the
various formulations available.
What was learned from the study?
Long-acting metformin formulations
(extended and delayed release) have equal
efficacy in glycaemic control compared to
immediate-release metformin
Metformin extended release is associated
with reduced LDL cholesterol
concentrations compared to immediate
release.
Metformin delayed release was associated
with reduced gastrointestinal side effects
compared to immediate release, which
could improve drug compliance.
Further research is required to refine the
optimal cost–benefit ratio of the different
available preparations of metformin in
various clinical circumstances.
DIGITAL FEATURES
This article is published with digital features,
including a summary slide, to facilitate under-
standing of the article. To view digital features
for this article go to https://doi.org/10.6084/
m9.figshare.14355116.
INTRODUCTION
Metformin (N,N-dimethylbiguanide) is increas-
ingly prescribed worldwide for a widening
variety of indications. In 2018, metformin was
prescribed over 80 million times, making it the
fourth most commonly prescribed drug in the
USA [1]. Metformin is included in the World
Health Organization (WHO) model list of
essential medicines [2], reflecting its increasing
use and suitability for low-resource settings.
Despite the very widespread clinical use of
metformin, there is a lack of systematic evi-
dence to guide optimal selection of the various
formulations available.
Metformin is primarily prescribed as an oral
glucose-lowering agent in the context of type 2
diabetes mellitus (T2DM). Metformin is effica-
cious in controlling hyperglycaemia and thus
minimising the long-term consequences of
diabetes [3]. Metformin exerts glucose-lowering
effects through several mechanisms including
suppressing hepatic gluconeogenesis (via AMPK
activation), downregulating lipogenic enzymes,
and inhibiting cellular respiration (via inhibi-
tion of mitochondrial complex I) [4–7]. Met-
formin is also prescribed for other indications,
including polycystic ovary syndrome (PCOS)
[8], gestational diabetes [9] and obesity [10],
although these uses are not licensed in the UK
or USA. A mounting body of evidence also
suggests that metformin may be of benefit in
diverse conditions such as cancer treatment
[11], dermatological conditions [12], pre-
eclampsia [13] and osteoarthritis [14].
A significant barrier to the use of metformin
is the high incidence of side effects, particularly
gastrointestinal (GI) symptoms. Of all patients
who take metformin, 20–30% report GI side
effects; and approximately 5% of all patients
discontinue treatment because of severe GI
symptoms [15]. The concentration of met-
formin measured in the small intestine peaks at
30–300 times greater than plasma concentra-
tions [16]; thus it has been suggested that
intestinal accumulation of metformin may be a
key driver of the reported GI side effects [17]. It
is therefore plausible that different formulations
of metformin, absorbed systemically at different
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rates and locations in the GI tract, may have
significantly different GI side effect profiles.
Metformin hydrochloride (metformin immedi-
ate release, met-IR), is poorly absorbed in the
stomach [18], so the majority of the drug is
absorbed in the upper part of the small intes-
tine. Metformin extended release (met-XR) is a
formulation of metformin hydrochloride sus-
pended within a polymer matrix that dissolves
over hours as the tablet passes through the GI
tract. Peak metformin concentrations in the
small intestine are thus reduced with met-XR
compared to met-IR [19]. The newest formula-
tion of metformin is metformin delayed release
(met-DR) [19, 20]. Met-DR is distinct from met-
XR in that it comprises a core of metformin
hydrochloride with a pH-dependent enteric
coating, which dissolves at pH C 6.5. Hence
drug delivery is targeted to the ileum, max-
imising the gut-based mechanisms of action of
metformin while reducing bioavailability.
Longer-acting formulations thus reduce sys-
temic absorption of metformin [18, 19]. It is
possible that lower doses of met-XR or met-DR
could be used to achieve similar efficacy to met-
IR while simultaneously reducing prevalence of
side effects.
We systematically compared the efficacy and
side effect profiles of met-IR, met-XR and met-
DR. Despite the increased costs of longer-acting
preparations of metformin, if there are signifi-
cant gains in tolerability then increased use of
these formulations may ultimately improve
concordance, increase achievement of treat-
ment goals and thus ultimately reduce spending
within healthcare services.
METHODS
This systematic review and meta-analysis was
conducted in accordance with the Preferred
Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA) guidelines [21]. The
systematic review protocol was registered
prospectively in PROSPERO (CRD42020167692;
Supplementary Text S1) prior to data collection.
This article is based on previously conducted
studies and does not contain any new studies
with human participants or animals performed
by any of the authors and therefore ethical
approval was not required.
Literature Searches, Search Strategies
and Eligibility Criteria
Systematic literature searches using pre-speci-
fied terms (Supplementary Text S2) were per-
formed on PubMed, Ovid EMBASE, Ovid
Medline, Cochrane library, Clinicaltrials.gov
and Web of Science from database inception to
25 January 2021. No language or location
restrictions were applied. Studies that ran-
domised adults to any ‘extended-release’ for-
mulation of metformin (encompassing slow-
release, extended-release, controlled-release and
delayed-release preparations) versus immediate-
release metformin (met-IR) were included
(Supplementary Table S1). Studies were inclu-
ded if they randomised patients for any indi-
cation. All treatment indications were screened
for and diagnosed according to local criteria in
each study, and we did not apply exclusions
with respect to this. No restrictions were applied
with respect to the length of follow-up period.
Efficacy outcomes were change in fasting
plasma glucose (FPG; mg/dl and mmol/l),
change in glycated haemoglobin (HbA1c; %),
body mass index (BMI; kg/m2), mean body
weight (kg), lipid profiles (including total, HDL,
LDL cholesterol and triglycerides; mg/dl). Any
side effects, including GI effects, reported by
individual studies were recorded. Data reported
only in meeting abstracts was included if the
abstract contained sufficient information for
assessment. One meeting abstract [22] con-
tained sufficient information and therefore was
included in the meta-analysis. Where insuffi-
cient information for complete assessment was
available, authors were contacted for further
information. A total of seven authors were
contacted; however none responded.
Study Selection and Data Extraction
Two reviewers (JLT-A and IDG) independently
assessed each study using pre-determined
inclusion/exclusion criteria (Supplementary
Table 1). A third reviewer (CEA) was available to
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resolve cases where eligibility was unclear. An
initial screen of titles and abstracts was per-
formed, followed by a detailed full paper screen
(Supplementary Fig. S1). Data extraction from
eligible studies was conducted independently
using a standardized pro forma by two authors
(JLT-A and IDG) with a third author (CEA)
available if required.
Quality Assessment (Risk of Bias)
Each study was independently assessed by two
authors (JLT-A and IDG) for quality and validity
using the Cochrane Collaboration tool for
assessing risk of bias. A third reviewer (CEA) was
available to resolve cases where risk of bias was
unclear. Seven risk of bias domains were sys-
tematically assessed for each study and each
domain was given a rating of low risk, unknown
risk or high risk of bias (Supplementary
Table S2). All risk of bias analysis was conducted
at the study level.
Statistical Analysis
The principal summary measures were unad-
justed odds ratios (OR) (for dichotomous data)
or mean difference (MD) (for continuous data).
Meta-analysis and meta-regression were per-
formed using Review Manager (RevMan Version
5.3, Copenhagen: The Nordic Cochrane Centre,
the Cochrane Collaboration, 2014) and the
metafor package in R version 3.5.1 (R Founda-
tion for Statistical Computing, Vienna, Austria).
Funnel plots were constructed to assess publi-
cation bias. Meta-analyses with five or more
studies included were also subjected to Egger’s
test. Heterogeneity between studies was assessed
using the I2 statistic. We implemented random-
effects meta-analyses using restricted maxi-
mum-likelihood (REML) estimator. Meta-re-
gression was performed with fasting plasma
glucose as the dependent variable and met-
formin dose as the predictor variable. Sensitivity
analyses were performed using ‘leave-one-out’
(LOO) analysis for individual studies. All studies
were analysed according to intention-to-treat.
All outcomes were subjected to Grading of
Recommendations, Assessment, Development
and Evaluation (GRADE) analysis (GRADEpro
Guideline Development Tool, McMaster
University, USA). Where p values are reported,
an alpha level\0.05 was considered statisti-
cally significant.
RESULTS
Study Selection and Study Characteristics
The PRISMA flow chart (Supplementary Fig. S1)
demonstrates the screening procedure involved
to include 15 eligible studies (n = 3765 partici-
pants). The majority of these studies (12 studies,
involving 2934 participants) compared met-XR
v. met-IR [22–33]. One study (n = 571) com-
pared met-DR v. met-IR [20]. The remaining two
studies (n = 260) compared met-DR, met-XR
and met-IR [19, 34].
The majority of studies enrolled people with
type 2 diabetes (13 studies; n = 3119). One
study (n = 571) enrolled people with T2D and
chronic kidney disease (CKD I/II) [20] and one
study enrolled people with PCOS (n = 75) [22].
For all indications and comparisons, the
studies varied with respect to quality and design
(Supplementary Table S3). The included studies
demonstrated heterogeneity with respect to the
dosage of metformin (600–2500 mg) and the
study duration (Supplementary Table S3). The
included studies came from a variety of geo-
graphical locations: Europe (Belgium, Italy),
Africa/Middle East (Pakistan, South Africa), Asia
(China and Taiwan) and North America /Latin
America (USA and Brazil).
Risk of Bias and Sensitivity Analyses
The risk of bias was moderate-to-low in the
majority of included studies; however two
studies were open-label [27, 29]. Removal of
these two studies did not substantively alter any
outcomes, therefore all were included. We
assessed the likelihood of single studies signifi-
cantly influencing the overall results using LOO
analysis (Supplementary Fig. S2) for met-IR v.
met-XR comparisons. Two outcome measures
investigated failed LOO analysis: change in
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body weight and likelihood of vomiting. This
decreases our confidence of the robustness of
these findings. Funnel plots for all outcomes
were assessed visually (Supplementary Fig. S3);
there were no obvious asymmetries in the plots
for any study outcomes. All outcomes with
more than five studies were subject to Egger’s
test, and all passed.
GRADE Analysis (Certainty of Evidence)
The majority of outcomes were classified as
having a moderate certainty of evidence
(Supplementary Fig. S4), with one outcome
having a high certainty of evidence (LDL
cholesterol). The moderate certainty of evi-
dence was due to from five outcomes having
high heterogeneity between studies and four
outcomes having high degrees of imprecision in
the derived estimates. No publication bias (as
ascertained by the Egger’s testing and funnel
plot analyses) was detected. All studies reported
direct evidence (Supplementary Fig. S4).
Fig. 1 Effect of metformin formulations (met-XR, met-IR
and met-DR) upon mean fasting plasma glucose concen-
trations (mg/dl) measured at the start and at the end of the
study. Metformin doses range between 600 mg per day to
2000 mg. Summary measures expressed as doses between
1000 and 1500 mg per day. Mean difference and 95%
confidence intervals
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SYNTHESIS OF RESULTS
Efficacy Outcomes
Mean Change in FPG
Ten studies (n = 2855) reported either change in
FPG or start-and-finish FPG concentrations over
33 separate groups. Of these, two groups were
intermediate measurements of the same partic-
ipants, so 31 groups (n = 2499) were included in
meta-analysis (9 met-IR, 15 met-XR, 7 met-DR).
When summary measures were calculated using
comparable dosages (1000–1500 mg), there was
no significant difference between the efficacy of
met-IR, met-XR or met-DR in changing FPG
(p = 0.928, Fig. 1); met-IR, - 22.90 ± 21.70 mg/
dl (1.30 ± 1.20 mmol/l): met-XR, - 21.90 ±
9.90 mg/dl (1.2 ± 0.6 mmol/l); met-DR,
- 20.00 ± 5.60 mg/dl (1.10 ± 0.30 mmol/l).
All 33 groups were included in meta-regres-
sion (10 met-IR, 16 met-XR, 7 met-DR,
n = 2855). Met-IR was only reported at two
doses, so meta-regression could not reasonably
be performed. There was significant dose-de-
pendency of change in FPG for both met-DR
and met-XR. For every 1000 mg dose, FPG
decreased by 0.90 ± 0.40 mmol/l
(15.60 ± 7.70 mg/dl; p\0.05) with met-XR
and 1.00 ± 0.40 mmol/l (18.1 ± 6.4 mg/dl;
p\0.01) with met-XR (Fig. 2).
Mean Change in HbA1c
Nine studies (n = 2037) reported HbA1c change
or start and finish HbA1c concentrations over
29 separate groups (8 met-IR, 14 met-XR, 7 met-
DR). When summary measures were calculated
using comparable dosages (1000–1500 mg),
there was no significant difference between the
efficacy of met-IR, met-XR or met-DR in reduc-
ing HbA1c (p = 0.25; met-IR, - 0.66 [- 1.04,
- 0.27], p\ 0.001; met-XR, - 0.70 [ - 0.81,
- 0.58], p\ 0.0001; met-DR, - 0.50 [- 0.70,
- 0.29], p\0.0001) (Fig. 3).
Mean Body Weight and BMI
Three studies including 829 participants repor-
ted mean body weight for met-IR vs. met-XR.
There was a non-significant decrease in post-
treatment mean body weight in individuals
randomised to met-XR vs. met-IR (- 1.03
[- 2.12, 0.05], p = 0.06) (Fig. 4a). Three studies
(n = 430) reported post-treatment BMI for met-
IR vs. met-XR. There was no significant differ-
ence in post-treatment BMI between partici-
pants randomised to met-XR v. met-IR (Fig. 4b).
No included studies involving met-DR reported
these outcomes.
Lipid Profile
There were no significant differences in the
concentrations of total cholesterol, HDL
cholesterol or triglycerides observed in partici-
pants randomised to met-XR versus met-IR
(Table 1). Individuals randomised to met-XR
had significantly decreased post-treatment LDL
cholesterol concentrations compared to those
randomised to met-IR (Table 1).
Side Effects of Metformin Formulations
There was a non-statistically significant reduc-
tion in the likelihood of experiencing GI side
effects between individuals randomised to met-
XR versus met-IR (OR 0.69, 95% CI 0.45–1.07,
I2 = 71%, p = 0.10), based on nine studies
including 2164 participants (Fig. 5a). Individu-
als randomised to met-DR versus met-IR were
Fig. 2 Meta-regression of the effect of metformin formu-
lations (met-XR, met-IR and met-DR) upon the change in
fasting plasma glucose concentrations
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less than half as likely to experience any GI side
effects (OR 0.45, 95% CI 0.26–0.80, I2 = N/A,
p = 0.006), based on one study including 472
participants (Fig. 5b). There was no significant
difference in the likelihood of developing any
GI side effects between individuals randomised
to met-DR versus met-XR (OR 0.84, 95% CI
0.32–2.19, I2 = N/A, p = 0.72), in one study
including 159 participants (Fig. 5c). When each
reported side effect was considered separately,
randomisation to met-XR versus met-IR was
associated with reduced likelihood of heart-
burn/dyspepsia and increased tolerability over-
all (Table 2). Randomisation to met-DR v met-IR
was associated with reduced likelihood of nau-
sea (Table 2). No studies comparing met-DR
versus met-XR reported the likelihood of expe-
riencing each side effect separately.
DISCUSSION
Main Findings
Our findings suggest that in people with T2DM
and/or PCOS there were no significant differ-
ences in efficacy of glycaemic control between
all included metformin formulations (IR, XR
Fig. 3 Effect of metformin formulations (met-XR, met-IR
and met-DR) upon mean HbA1c concentrations (%)
measured at the start and at the end of the study.
Metformin doses range between 600 mg per day to
2000 mg. Summary measures expressed as doses between
1000 and 1500 mg per day. Mean difference and 95%
confidence intervals
Diabetes Ther (2021) 12:1901–1914 1907
Fig. 4 Effect of metformin formulations upon a mean body weight (kg) and b mean BMI (kg/m2). Only comparisons
available were met-XR versus met-IR. Mean difference and 95% confidence intervals
Table 1 Post-treatment lipid profile
Lipid parameter Mean diff [95% CI] Study no. (n) I2 (%) P value
Total cholesterol – 2.90 [– 6.09, 0.30] 6 (1831) 44 0.08
HDL cholesterol 0.25 [– 0.61, 1.11] 4 (1560) 0 0.56
LDL cholesterol – 5.50 [– 8.08, – 2.92] 4 (1550) 30 \ 0.0001
Triglycerides 1.22 [– 3.28, 5.72) 6 (1725) 29 0.60
Lipid levels (mg/dl)
All comparisons are met-DR v. met-IR. No studies comparing met-DR v. met-IR or met-DR vs. met-XR reported post-
treatment lipid profiles
diff difference, met metformin, DR delayed-release, XR extended-release, IR immediate-release
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and DR), based on change in FPG and in HbA1c
after treatment. In addition, our analyses
showed very similar reductions in FPG with
randomisation to met-XR versus met-DR across
a range of clinically relevant doses. There was
no significant difference in the magnitude of
weight loss experienced by patients randomised
to different metformin formulations or in the
change in their BMI during treatment. How-
ever, patients randomised to met-XR had sig-
nificantly reduced LDL cholesterol levels
compared to those randomised to met-IR. GI
side effects were markedly reduced in patients
randomised to longer-acting metformin
Fig. 5 Effect of metformin formulations upon overall gastrointestinal side effects in a met-XR versus met-IR, b met-DR vs.
met-IR and c met-DR versus met-XR. Odds ratio and 95% confidence interval
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preparations compared to met-IR, particularly
with met-DR.
Strengths
Our analyses provides the first systematic com-
parison of the three formulations of metformin
that have currently been trialled in head-to-
head trials. Meta-regression and extensive sen-
sitivity analyses have been performed to opti-
mise comparisons between available studies and
to leverage all existing data, despite method-
ological differences between the original stud-
ies, for example in dosing and study length.
There are few previous syntheses of data directly
comparing preparations of metformin. A previ-
ous comprehensive review concluded that side
effects were reduced with met-XR compared to
IR, but predated the availability of the new met-
DR formulation [35].
Limitations
The drawing of definitive conclusions from our
meta-analysis was limited by both the quantity
and quality of the studies available. In particu-
lar, there was a lack of studies involving com-
parisons of individuals randomised to met-DR
vs. met-IR (one study; n = 571) [20] or met-DR
vs. met-XR (two studies; n = 260) [19, 34]. We
thus suggest a cautious view regarding the
interpretation of these comparisons. Our results
highlight the need for more high-quality stud-
ies investigating optimal use of various met-
formin formulations, particularly in patient
populations other than type 2 diabetes. More-
over, if more and higher quality data were
available then non-significant effects, for
example reduction in total cholesterol levels
with met-XR v. met-IR, might reach signifi-
cance, as would be expected from the observed
reduction in LDL cholesterol. While metformin
Table 2 Separate side effects
Adverse effect Comparison Mean diff [95% CI] Study no. (patients) P value I2 (%)
Diarrhoea met-XR vs. met-IR 0.87 [0.43, 1.41] 8 (2063) 0.41 64
met-DR vs. met-IR 0.67 [0.34, 1.31] 1 (477) 0.24 N/A
Vomiting met-XR vs. met-IR 0.90 [0.37, 2.18] 3 (920) 0.82 30
met-DR vs. met-IR – – –
Nausea met-XR vs. met-IR 0.83 [0.57, 1.21] 7 (2036) 0.34 0
met-DR vs. met-IR 0.25 [0.12, 0.52] 1 (475) 0.004 0
Abdominal pain/bloating met-XR vs. met-IR 1.24 [0.76, 2.03] 7 (2011) 0.39 0
met-DR vs. met-IR – – – –
Flatulence met-XR vs. met-IR 0.71 [0.09, 5.44] 3 (526) 0.75 66
met-DR vs. met-IR – – – –
Heartburn/dyspepsia met-XR vs. met-IR 0.49 [0.25, 0.97] 4 0.04 0
met-DR vs. met-IR – – – –
Headache met-XR vs. met-IR 0.99 [0.39, 2.52] 2 0.98 0
met-DR vs. met-IR – – – –
Overall drug tolerance met-XR vs. met-IR 0.25 [0.16, 0.38] 1 \ 0.00001 N/A
met-DR vs. met-IR – – – –
diff difference, met metformin, DR delayed-release, XR extended-release, IR immediate-release
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is prescribed for a range of clinical indications,
the studies available for inclusion in our meta-
analysis were limited mainly to populations
with T2DM. We were thus only able to compare
the efficacy of different metformin formulations
for outcomes related to T2DM: glycaemic con-
trol, body weight and lipid profiles.
Interpretation
Despite the frequent and widespread prescrip-
tion of metformin worldwide, there is a relative
lack of head-to-head comparison data regarding
optimal formulations. This information is
important to help guide decision-making about
the cost–benefit ratio of prescribing long-acting
metformin preparations; in some circumstances
the relatively high upfront cost of these prepa-
rations may make their use prohibitive, despite
potential clinical advantages [36]. The equal
efficacies of the different metformin formula-
tions in lowering glucose, despite significant
differences in drug plasma concentrations, may
be explained at least in part by the importance
of the gut-based mechanisms of action of met-
formin, for example stimulating glucagon-like
peptide 1 (GLP-1)/peptide YY secretion, alter-
ations of bile acid metabolism and potentially
changes to the gut microbiome [17].
In our analysis, mean body weight was
reduced following treatment with metformin,
regardless of formulation. The underlying
mechanism of metformin-associated weight
loss remains poorly understood and is likely
multifactorial, with several possible contribut-
ing mechanisms. Metformin-associated weight
loss may be centrally mediated via suppression
of orexigenic hypothalamic neurons potentially
via GDF-15 [37], by decreased expression of
neuropeptide Y, or by preventing ghrelin-me-
diated appetite stimulation [38]. There is likely
also to be an important contribution from gut-
based mechanisms, including increased secre-
tion of GLP-1 [39]. It has also been suggested
that GI side effects may contribute to met-
formin-associated weight loss via malabsorption
of bile salts, microbiome alteration or and gut
serotonin secretion [39]. Although we found
that long-acting preparations of metformin
were associated with reduced GI side effects
compared to immediate-release metformin,
there was no significant difference in the mag-
nitude of weight loss associated with long-act-
ing preparations, suggesting that GI side effects
were not the main mediators of weight loss.
Metformin improves lipid profiles by
decreasing the activity and expression of several
products involved in lipid synthesis, including
acetyl CoA carboxylase (ACCase), sterol regula-
tory element-binding protein 1 (SREBP-1), fatty
acid synthase (FAS) and HMG CoA reductase
(HMGCR) [39]. We found that people ran-
domised to met-XR versus met-IR had reduced
LDL cholesterol levels, suggesting that long-
acting metformin may show some benefit over
the immediate-release formulation in improv-
ing long-term cardio-metabolic risk profiles.
CONCLUSIONS
Our results demonstrate equal efficacy of
longer-acting (XR, DR) versus IR metformin
formulations in terms of glycaemic control, but
significant additional advantages with the
longer-acting formulations. Metformin XR was
associated with reduced serum LDL cholesterol
concentrations, while metformin DR was
strongly associated with reduced GI side effects,
which could improve drug compliance. Further
research is required to refine the optimal
cost–benefit ratio of the different available
preparations of metformin in various clinical
circumstances.
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